Glipizide is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available as tablets and extended-release tablets for oral use. MedsAcross supplies Glipizide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
GLUCOTROL XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOTROL XL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis
Source: US FDA prescribing information
Glipizide primarily lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
Source: US FDA prescribing information
• Recommended starting dose is 5 mg once daily. Dose adjustment can be made based on the patient's glycemic control. Maximum recommended dose is 20 mg once daily. • Administer with breakfast or the first meal of the day. • For combination therapy with other blood-glucose-lowering agents, initiate the agent at the lowest recommended dose, and observe patients for hypoglycemia.
Source: US FDA prescribing information
Glipizide is contraindicated in patients with: • Known hypersensitivity to glipizide or any of the product's ingredients. • Hypersensitivity to sulfonamide derivatives. • Known hypersensitivity to glipizide or any of the product's ingredients. • Hypersensitivity to sulfonamide derivatives.
Source: US FDA prescribing information
• Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications. • Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. • Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives. • Macrovascular Outcomes: No clinical studies have established conclusive evidence of macrovascular risk reduction with GLUCOTROL XL or any other anti-diabetic drug.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: • Hypoglycemia • Hemolytic anemia Most common adverse reactions (incidence > 3%) are dizziness, diarrhea, nervousness, tremor, hypoglycemia and flatulence.
Source: US FDA prescribing information
• Certain medications may affect glucose metabolism, requiring GLUCOTROL XL dose adjustment and close monitoring of blood glucose. • Miconazole: Monitor patients closely. Severe hypoglycemia can occur when GLUCOTROL and oral miconazole are used concomitantly. • Fluconazole: Monitor patients closely. An increase in GLUCOTROL AUC was seen after fluconazole administration. • Colesevelam: GLUCOTROL XL should be administered at least 4 hours prior to colesevelam.
Source: US FDA prescribing information
Store at 68–77°F (20–25°C), excursions permitted between 59°F and 86°F (15°C and 30°C). The tablets should be protected from moisture and humidity.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Glipizide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Glipizide 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 10 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 5 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 2.5 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 2.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Glipizide 15 mg tabletOralGeneric name | — | US FDA | Available on request |
| Glucotrol XL 5 mg extended-release tabletOral | Roerig | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 8 May 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Glipizide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Glipizide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Glipizide, including Glucotrol XL.
Yes. The US FDA first approved Glipizide on 8 May 1984, according to Drugs@FDA.
No listed presentation of Glipizide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Glipizide is classified under ATC code A10BB07 (Glipizide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.